J. Paul Secrist

3.8k total citations · 1 hit paper
25 papers, 2.0k citations indexed

About

J. Paul Secrist is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, J. Paul Secrist has authored 25 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Molecular Biology, 10 papers in Oncology and 5 papers in Immunology. Recurrent topics in J. Paul Secrist's work include Histone Deacetylase Inhibitors Research (13 papers), Protein Degradation and Inhibitors (7 papers) and Peptidase Inhibition and Analysis (7 papers). J. Paul Secrist is often cited by papers focused on Histone Deacetylase Inhibitors Research (13 papers), Protein Degradation and Inhibitors (7 papers) and Peptidase Inhibition and Analysis (7 papers). J. Paul Secrist collaborates with scholars based in United States, Australia and Japan. J. Paul Secrist's co-authors include Robert T. Abraham, Larry M. Karnitz, Victoria M. Richon, Gary A. Koretzky, L A Burns, Paul A. Marks, William Kevin Kelly, William P. Tong, Mark Heaney and Tracy Curley and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Nature Communications.

In The Last Decade

J. Paul Secrist

25 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase I Study of an Oral Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, in Patients With Advanced Cancer

2005 739 citations William Kevin Kelly, J. Paul Secrist et al. profile →

Peers

Countries citing papers authored by J. Paul Secrist

Since Specialization

Citations

This map shows the geographic impact of J. Paul Secrist's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Paul Secrist with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Paul Secrist more than expected).

Fields of papers citing papers by J. Paul Secrist

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Paul Secrist. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Paul Secrist. The network helps show where J. Paul Secrist may publish in the future.

Co-authorship network of co-authors of J. Paul Secrist

This figure shows the co-authorship network connecting the top 25 collaborators of J. Paul Secrist. A scholar is included among the top collaborators of J. Paul Secrist based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Paul Secrist. J. Paul Secrist is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Multiscale Model Identifies Improved Schedule for Treatment of Acute Myeloid Leukemia In Vitro With the Mcl‐1 Inhibitor AZD5991 2020 ·CPT Pharmacometrics & Systems Pharmacology ·Ardeshir Goliaei, (unknown), Adriana E. Tron, Matthew A. Belmonte, J. Paul Secrist, Douglas Ferguson, Lisa Drew, Adrian J. Fretland, Bree B. Aldridge, Francis D. Gibbons	3
2	Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapies 2019 ·Nature Communications ·Joan Montero, Cécile Gstalder, Daniel J. Kim, (unknown), Wayne Miles, Michael P. Manos, Justin Cidado, J. Paul Secrist, Adriana E. Tron, Keith T. Flaherty, F. Stephen Hodi, Charles H. Yoon, Anthony Letai, David E. Fisher, Rizwan Haq	42
3	Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas 2018 ·Blood ·Raphael Koch, Amanda L. Christie, Jennifer L. Crombie, Adam C. Palmer, Deborah Plana, (unknown), Sara Morrow, Alexandria Van Scoyk, Wenchao Wu, Elizabeth Brém, J. Paul Secrist, Lisa Drew, Alwin G. Schuller, Justin Cidado, Anthony Letai, David M. Weinstock	35
4	Abstract 311: AZD4320 is a potent, dual Bcl-2/xLinhibitor that rapidly induces apoptosis in preclinical hematologic tumor models 2018 ·Cancer Research ·Justin Cidado, J. Paul Secrist, Francis D. Gibbons, Edward J. Hennessy, Stephanos Ioannidis, Edwin Clark	5
5	Abstract DDT01-02: AZD5991: A potent and selective macrocyclic inhibitor of Mcl-1 for treatment of hematologic cancers 2017 ·Cancer Research ·Alexander W. Hird, J. Paul Secrist, Ammar Adam, Matthew A. Belmonte, Eric T. Gangl, (unknown), David Hargreaves, Jeffrey W. Johannes, (unknown), Jason G. Kettle, Stephen E. Kurtz, Michelle L. Lamb, Martin J. Packer, Bo Peng, (unknown), Jeffrey Tyner, Wenzhan Yang, Qing Ye, Xiaolan Zheng, Edwin Clark	15
6	Molecular and Biologic Analysis of Histone Deacetylase Inhibitors with Diverse Specificities 2013 ·Molecular Cancer Therapeutics ·Andrea Newbold, Geoffrey M. Matthews, Michael Bots, Leonie A. Cluse, Christopher J. Clarke, (unknown), Carleen Cullinane, Jessica E. Bolden, Ailsa J. Christiansen, Ross A. Dickins, Claudia Miccolo, Susanna Chiocca, Astrid M. Kral, Nicole Ozerova, Thomas A. Miller, Joey L. Methot, Victoria M. Richon, J. Paul Secrist, Saverio Minucci, Ricky W. Johnstone	40
7	Exploring the pharmacokinetic properties of phosphorus-containing selective HDAC 1 and 2 inhibitors (SHI-1:2) 2009 ·Bioorganic & Medicinal Chemistry Letters ·Richard W. Heidebrecht, Mélissa Chénard, (unknown), William K. Dahlberg, Judith C. Fleming, Jonathan B. Grimm, (unknown), Andreas Harsch, Brian B. Haines, Bethany Hughes, Astrid M. Kral, Richard E. Middleton, (unknown), Nicole Ozerova, Alexander A. Szewczak, (unknown), Kevin J. Wilson, David J. Witter, J. Paul Secrist, Thomas A. Miller	17
8	Phenylglycine and phenylalanine derivatives as potent and selective HDAC1 inhibitors (SHI-1) 2008 ·Bioorganic & Medicinal Chemistry Letters ·Kevin J. Wilson, David J. Witter, Jonathan B. Grimm, Phieng Siliphaivanh, Karin M. Otte, Astrid M. Kral, Judith C. Fleming, Andreas Harsch, (unknown), Jonathan C. Cruz, Mélissa Chénard, Alexander A. Szewczak, Richard E. Middleton, Bethany Hughes, William K. Dahlberg, J. Paul Secrist, Thomas A. Miller	20
9	SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2) 2008 ·Bioorganic & Medicinal Chemistry Letters ·Joey L. Methot, Christopher L. Hamblett, (unknown), Joon Jung, Andreas Harsch, Alexander A. Szewczak, William K. Dahlberg, Richard E. Middleton, Bethany Hughes, Judith C. Fleming, (unknown), Astrid M. Kral, Nicole Ozerova, Jonathan C. Cruz, Brian B. Haines, Mélissa Chénard, Candia M. Kenific, J. Paul Secrist, Thomas A. Miller	36
10	Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist 2008 ·Proceedings of the National Academy of Sciences ·Ailsa J. Frew, Ralph K. Lindemann, Ben P. Martin, Christopher J. Clarke, Janelle Sharkey, (unknown), Kellie-Marie Banks, Nicole M. Haynes, Pradnya Gangatirkar, Kym L. Stanley, Jessica E. Bolden, Kazuyoshi Takeda, Hideo Yagita∥, J. Paul Secrist, Mark J. Smyth, Ricky W. Johnstone	118
11	Benzo[b]thiophene-based histone deacetylase inhibitors 2007 ·Bioorganic & Medicinal Chemistry Letters ·David J. Witter, Sandro Belvedere, Liqiang Chen, J. Paul Secrist, Ralph T. Mosley, Thomas A. Miller	31
12	Aminosuberoyl hydroxamic acids (ASHAs): A potent new class of HDAC inhibitors 2007 ·Bioorganic & Medicinal Chemistry Letters ·Sandro Belvedere, David J. Witter, Jiaming Yan, J. Paul Secrist, Victoria M. Richon, Thomas A. Miller	30
13	Amino acid derivatives as histone deacetylase inhibitors 2007 ·Bioorganic & Medicinal Chemistry Letters ·Jed L. Hubbs, Hua Zhou, Astrid M. Kral, Judith C. Fleming, William K. Dahlberg, Bethany Hughes, Richard E. Middleton, Alexander A. Szewczak, J. Paul Secrist, Thomas A. Miller	15
14	Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2) 2007 ·Bioorganic & Medicinal Chemistry Letters ·David J. Witter, Paul E. Harrington, Kevin J. Wilson, Mélissa Chénard, Judith C. Fleming, Brian B. Haines, Astrid M. Kral, J. Paul Secrist, Thomas A. Miller	80
15	Interspecies comparison of the pharmacokinetics and metabolism of SAHA 2004 ·Cancer Research ·Paul A. Andrews, Thomas A. Miller, Gohar Mushtaq, (unknown), J. Paul Secrist, Victoria M. Richon	1
16	Histone Deacetylase Inhibitors: Assays to Assess Effectiveness In Vitro and In Vivo 2003 ·Methods in enzymology on CD-ROM/Methods in enzymology ·Victoria M. Richon, Xianbo Zhou, J. Paul Secrist, Carlos Cordon‐Cardo, William Kevin Kelly, Marija Drobnjak, Paul A. Marks	14
17	Full Activation of the Platelet-derived Growth Factor β-Receptor Kinase Involves Multiple Events 1998 ·Journal of Biological Chemistry ·Ruth Baxter, J. Paul Secrist, Richard R. Vaillancourt, Andrius Kazlauskas	92
18	The GTPase-Activating Protein of Ras Suppresses Platelet-Derived Growth Factor β Receptor Signaling by Silencing Phospholipase C-γ1 1995 ·Molecular and Cellular Biology ·Mindaugas Valius, J. Paul Secrist, Andrius Kazlauskas	46
19	Signal transduction through the T-cell antigen receptor 1992 ·Trends in Biochemical Sciences ·Robert T. Abraham, Larry M. Karnitz, J. Paul Secrist, Paul J. Leibson	39
20	Signal transduction through the T cell antigen receptor. Activation of phospholipase C through a G protein-independent coupling mechanism 1991 ·The Journal of Immunology ·James A. Augustine, J. Paul Secrist, (unknown), Paul J. Leibson, Robert T. Abraham	24

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact